Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference (GlobeNewswire) - Sep 11, 2023 - "Plus Therapeutics, Inc...announced that the Company will present data from its ReSPECT-LM clinical trial evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases at the Cancer Prevention & Research Institute of Texas (CPRIT) Innovations in Cancer Prevention and Research Conference VI....In August 2023, Plus Therapeutics received an advance payment of grant funds of approximately $1.9 million, as planned, as part of its overall $17.6 million award contract, which CPRIT executed in September 2022. The contract provides for funding from CPRIT over the three-year grant period starting on August 31, 2022, and follows the expected increase of development costs as the ReSPECT-LM clinical trial progresses to later stages."
Financing • P1 data • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|